← Eichor
Study identifier: NCT06643416 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

Condition: Paronychia · EGFR-TKI · ALK-TKI  ·  Sponsor: Queen Mary Hospital, Hong Kong

PhasePhase 3
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.

This description comes directly from the study's public registry record.

Talk to the study team

Wang Chun Kwok  ·  +85222555336  ·  kwokwch@hku.hk

Always discuss trial participation with your own doctor first.

Locations (1)

Queen Mary HospitalHong Kong, Hong KongRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06643416